Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Novak

Showing results (291-300 of 332) with videos related to

Pageof 34
Sort By:
BMC Public Health|April 1, 2024
Participatory development of an mHealth intervention delivered in general practice to increase physical activity and reduce sedentary behaviour of patients with prediabetes and type 2 diabetes (ENERGISED)Jan Novak, Katerina Jurkova, Anna Lojkaskova, et al.
Blood|September 16, 2022
Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Swiss Medical Weekly|July 12, 2017
Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillationDavid Conen, Nicolas Rodondi, Andreas Mueller, et al.
Blood Cancer Journal|October 27, 2021
Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood|March 29, 2020
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trialAndrew H Wei, Pau Montesinos, Vladimir Ivanov, et al.
Blood Cancer Journal|October 2, 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood|April 15, 2025
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapyNaval G Daver, Paresh Vyas, Gerwin A Huls, et al.
Journal of the American Society of Nephrology : JASN|October 15, 2011
APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathyNatalia Papeta, Krzysztof Kiryluk, Ami Patel, et al.
Blood Cancer Journal|April 21, 2022
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemiaKeith W Pratz, Panayiotis Panayiotidis, Christian Recher, et al.
Plos Genetics|February 11, 2017
GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathwayKrzysztof Kiryluk, Yifu Li, Zina Moldoveanu, et al.
Pageof 34

Showing results (291-300 of 332) with videos related to

Sort By:
Pageof 34
BMC Public Health|April 1, 2024
Participatory development of an mHealth intervention delivered in general practice to increase physical activity and reduce sedentary behaviour of patients with prediabetes and type 2 diabetes (ENERGISED)Jan Novak, Katerina Jurkova, Anna Lojkaskova, et al.
Blood|September 16, 2022
Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Swiss Medical Weekly|July 12, 2017
Design of the Swiss Atrial Fibrillation Cohort Study (Swiss-AF): structural brain damage and cognitive decline among patients with atrial fibrillationDavid Conen, Nicolas Rodondi, Andreas Mueller, et al.
Blood Cancer Journal|October 27, 2021
Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood|March 29, 2020
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trialAndrew H Wei, Pau Montesinos, Vladimir Ivanov, et al.
Blood Cancer Journal|October 2, 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Blood|April 15, 2025
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapyNaval G Daver, Paresh Vyas, Gerwin A Huls, et al.
Journal of the American Society of Nephrology : JASN|October 15, 2011
APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathyNatalia Papeta, Krzysztof Kiryluk, Ami Patel, et al.
Blood Cancer Journal|April 21, 2022
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemiaKeith W Pratz, Panayiotis Panayiotidis, Christian Recher, et al.
Plos Genetics|February 11, 2017
GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathwayKrzysztof Kiryluk, Yifu Li, Zina Moldoveanu, et al.
Pageof 34